Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 651-661 , October 2010

Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell–stimulatory capacity

  • Corbin Clawson, BS

      Affiliations

    • Department of Bioengineering, University of California San Diego, La Jolla, California, USA
    • These two authors contributed equally to this work.
    • ,
  • Chien-Tze Huang, BS

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • These two authors contributed equally to this work.
    • ,
  • Diahnn Futalan, BS

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • ,
  • Daniel Martin Seible, BS

      Affiliations

    • Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, USA
    • ,
  • Rebecca Saenz, BS, MS

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • Department of Biomedical Sciences, University of California San Diego, La Jolla, California, USA
    • ,
  • Marie Larsson, PhD

      Affiliations

    • Division of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Lindkoeping, Sweden
    • ,
  • Wenxue Ma, MD, PhD

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • ,
  • Boris Minev, MD

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • ,
  • Fiona Zhang, PhD

      Affiliations

    • Department of Mechanical Engineering, University of California Riverside, Riverside California, USA
    • ,
  • Mihri Ozkan, PhD

      Affiliations

    • Department of Electrical Engineering, University of California Riverside, Riverside, California, USA
    • ,
  • Cengiz Ozkan, PhD

      Affiliations

    • Department of Mechanical Engineering, University of California Riverside, Riverside California, USA
    • ,
  • Sadik Esener, PhD

      Affiliations

    • Department of NanoEngineering, University of California San Diego, La Jolla, California, USA
    • ,
  • Davorka Messmer, PhD

      Affiliations

    • Moores Cancer Center, University of California San Diego, La Jolla, California, USA
    • Corresponding Author InformationCorresponding author: Moores Cancer Center, University of California San Diego, La Jolla, California 92093-0815, USA.

Received 12 June 2009 ,Accepted 6 March 2010.

References 

  1. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines. 2009;8:51–66
  2. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383–393
  3. Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine. 2003;21:1250–1255
  4. Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M, et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol. 2007;178:2979–2986
  5. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target. 2003;11:495–507
  6. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(d,l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22:2406–2412
  7. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release. 2002;85:247–262
  8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  9. Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, et al. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol. 2006;18:1563–1573
  10. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm. 2004;275:171–187
  11. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002;83:273–286
  12. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57:171–185
  13. Lemoine D, Preat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Control Release. 1998;54:15–27
  14. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005;511:191–198
  15. Lee SY, Oh JH, Kim JC, Kim YH, Kim SH, Choi JW. In vivo conjunctival reconstruction using modified PLGA grafts for decreased scar formation and contraction. Biomaterials. 2003;24:5049–5059
  16. Zhou T, Lewis H, Foster RE, Schwendeman SP. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release. 1998;55:281–295
  17. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116:1–27
  18. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693–1702
  19. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004;173:307–313
  20. Morelli AE, Zahorchak AF, Larregina AT, Colvin BL, Logar AJ, Takayama T, et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood. 2001;98:1512–1523
  21. Messmer D, inventor; Medimmune, Inc. assignee. Immunogenic compositions comprising HMGB1 polypeptides. European patent application: PTC/US2005/021691; US patent application US 11/570,695. 2008.
  22. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135–3142
  23. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440:808–812
  24. Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol. 2007;37:2063–2074
  25. Steinman RM. The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris). 2003;51:59–60
  26. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159–1164
  27. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, Mukai Y, et al. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Biochem Biophys Res Commun. 2008;366:408–413
  28. de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother. 2007;56:1251–1264
  29. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol. 2006;36:3371–3380
  30. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol. 2006;176:7335–7345
  31. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173:3148–3154
  32. Vogt A, Combadiere B, Hadam S, Stieler KM, Lademann J. Schaefer H, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+cells after transcutaneous application on human skin. J Invest Dermatol. 2006;126:1316–1322
  33. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006;117:979–988

 This work is supported by the U.S. Army Medical Research and Materiel Command under Agreement No. W81XWH-07-1-0412 (D.M.); 5 U54 CA119335 from the National Institutes of Health/National Cancer Institute, (S.E.), the Swedish Research Council (VR) AI52731 and the Swedish International Development Cooperation Agency (SIDA) and VINNMER (Vinnova) (M.L.).

 Corporate affiliations: Call/Recall Inc., Nanogen, Genoptix, OMM, Orimedix, and Ziva Corp. (S.E.). Corporate affiliations: Call/Recall Inc., Nanogen, Genoptix, OMM, Orimedix, and Ziva Corp. (S.E.).

PII: S1549-9634(10)00097-3

doi: 10.1016/j.nano.2010.03.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 651-661 , October 2010

Article Tools

* Image Usage & Resolution